Preliminary investigations on the expression of miR-CT3 in circulating microvesicles purified from collected plasma of few metastatic cancer (breast cancer and renal cell carcinoma) and OS patients, highlighted that 8 out of 13 patients presented lower miR-CT3 expression values in comparison to healthy control (Figure 7). This evidence concerns the gene CAGE1 and hereditary clear cell renal cell carcinoma.